Additionally, a recent study reported that another molecule, EPZ-011989, sharing a similar structure with EPZ-6438 could expand the inhibition range of EZH2 and improve pharmacodynamic and pharmacokinetic qualities in a mouse B cell lymphoma model [114]. Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.